Clinical trial
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral…
NCT00415519 · Tanabe Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00415519 |
|---|---|
| Title | Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III |
| Official title | An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis (ALS) |
| Intervention type | Drug |
| Interventions | MCI-186, Placebo of MCI-186 |
| Enrollment | 25 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Dec 25, 2006 |
| Last update posted | Jan 6, 2026 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: